San Diego, California (PRWEB) April 24, 2015 -- Leading Regenerative Veterinary Medicine company Vet-Stem, Inc., announced key milestones in its allogeneic stem-cell product development program and changes its’ name to VetStem Biopharma to properly reflect the corporate strategic direction.
“I am extremely pleased to announce that our allogeneic (donor) adipose stem cell development program has been kicked into high gear with the completion of our cGMP manufacturing facility and hiring of our new Director of Research and Development. I am delighted to officially welcome Kevin Hicok to our executive team as our Director of Research and Development” stated Dr Bob Harman (CEO and Chief Science Officer).
Kevin comes to VetStem, with over 20 years of research experience in the field of adult stem and regenerative cell therapeutics. His experience includes R&D positions with Osiris Therapeutics, Artecel Sciences, Cytori Therapeutics, and the Mayo Clinic. With his experience managing basic and applied research groups, as well as his expertise in applying GLP, GTP and cGMP quality standards to research practice, Kevin will support the VetStem Biopharma development team in the steps needed to gain FDA approval for allogeneic stem cell therapies in dogs, cats, and horses.
“VetStem’s total dedication to the patients’ needs reminds me of my tenure as a scientist at the Mayo Clinic. The science and the therapeutic possibilities are so exciting! I am proud to be part of such a dedicated group of people and help them take the company to the next level”, said Kevin Hicok.
“Everything we do today is geared towards meeting and exceeding pharmaceutical industry standards. We track cases through an internal reporting system. We approve our documents through an internal regulatory review process. We operate our company through a set of over 400 quality standard operating procedures. We are truly a bio-pharmaceutical company and our new name reflects this reality and our future directions” said Dr. Alexis Nahama (President and Chief Commercial Officer).
About VetStem Biopharma.
VetStem Biopharma is a veterinarian led company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 10,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem research team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance companion animal lives by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, Vet-Stem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.
Kristi Hauta, Vet-Stem, Inc., http://www.vet-stem.com/, +1 858-748-2004 Ext: 208, [email protected]